A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone Palmitate

Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.

Trial Locations (12)

Unknown

Baoding

Beijing

Changsha

Chengdu

Guangzhou

Hangzhou

Kunming

Nanjing

Shijiazhuang

Taiyuan

Wuhan

Xi'an

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT01947803 - A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia | Biotech Hunter | Biotech Hunter